A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer
{{output}}
Small cell lung cancer (SCLC) is a highly lethal malignancy with the 5-year survival rate of less than 7%. Chemotherapy-resistance is a major challenge for SCLC treatment in clinic. In the study, we developed a high-throughput drug screen strategy to identify ... ...
